IL128850A - Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture - Google Patents

Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Info

Publication number
IL128850A
IL128850A IL12885097A IL12885097A IL128850A IL 128850 A IL128850 A IL 128850A IL 12885097 A IL12885097 A IL 12885097A IL 12885097 A IL12885097 A IL 12885097A IL 128850 A IL128850 A IL 128850A
Authority
IL
Israel
Prior art keywords
cyclobutyl
chlorophenyl
unsubstituted
humans
substituted
Prior art date
Application number
IL12885097A
Other languages
English (en)
Other versions
IL128850A0 (en
Original Assignee
Abott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abott Gmbh & Co Kg filed Critical Abott Gmbh & Co Kg
Publication of IL128850A0 publication Critical patent/IL128850A0/xx
Publication of IL128850A publication Critical patent/IL128850A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
IL12885097A 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture IL128850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
IL128850A0 IL128850A0 (en) 2000-01-31
IL128850A true IL128850A (en) 2003-07-31

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12885097A IL128850A (en) 1996-09-21 1997-09-15 Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture

Country Status (26)

Country Link
US (3) US6174925B1 (xx)
EP (1) EP0927028A1 (xx)
JP (1) JP2001503737A (xx)
KR (1) KR20000048501A (xx)
CN (1) CN1237905A (xx)
AU (1) AU724488B2 (xx)
BG (1) BG64473B1 (xx)
BR (1) BR9711517A (xx)
CA (1) CA2266401C (xx)
CZ (1) CZ93699A3 (xx)
GB (1) GB9619757D0 (xx)
HR (1) HRP970505A2 (xx)
HU (1) HUP9904026A3 (xx)
ID (1) ID18320A (xx)
IL (1) IL128850A (xx)
MY (1) MY116150A (xx)
NO (1) NO991358D0 (xx)
NZ (1) NZ334580A (xx)
PL (1) PL332305A1 (xx)
RU (1) RU2245709C2 (xx)
SK (1) SK31999A3 (xx)
TR (1) TR199900618T2 (xx)
TW (1) TW580385B (xx)
UA (1) UA64726C2 (xx)
WO (1) WO1998011884A1 (xx)
ZA (1) ZA978450B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
ID27415A (id) * 1998-06-30 2001-04-05 Takeda Chemical Industries Ltd Komposisi farmaseutik
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
AU3712100A (en) 1999-06-01 2000-12-18 University Of Texas Southwestern Medical Center, The Method of treating hair loss using sulfonyl thyromimetic compounds
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) * 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
ZA200602056B (en) 2003-10-31 2007-05-30 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
CN101394847B (zh) 2006-01-06 2017-05-24 塞普拉柯公司 作为单胺重摄取抑制剂的环烷基胺类
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
RU2462451C2 (ru) 2006-09-15 2012-09-27 Ривайва Фармасьютикалс, Инк. Способ получения, способы применения и композиции циклоалкилметиламинов
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
EP2083867A1 (en) * 2006-11-22 2009-08-05 SK Chemicals, Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
CA2858837C (en) 2011-12-30 2022-08-30 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
JP2001503737A (ja) 2001-03-21
NZ334580A (en) 2000-09-29
RU2245709C2 (ru) 2005-02-10
NO991358L (no) 1999-03-19
ID18320A (id) 1998-03-26
IL128850A0 (en) 2000-01-31
GB9619757D0 (en) 1996-11-06
MY116150A (en) 2003-11-28
BR9711517A (pt) 1999-08-24
HUP9904026A2 (hu) 2000-05-28
UA64726C2 (uk) 2004-03-15
TR199900618T2 (xx) 1999-06-21
BG103277A (en) 2000-01-31
ZA978450B (en) 1999-03-19
NO991358D0 (no) 1999-03-19
US6617360B1 (en) 2003-09-09
KR20000048501A (ko) 2000-07-25
WO1998011884A1 (en) 1998-03-26
CZ93699A3 (cs) 1999-08-11
TW580385B (en) 2004-03-21
US6174925B1 (en) 2001-01-16
EP0927028A1 (en) 1999-07-07
BG64473B1 (bg) 2005-04-30
PL332305A1 (en) 1999-08-30
HUP9904026A3 (en) 2000-07-28
CA2266401A1 (en) 1998-03-26
AU4774097A (en) 1998-04-14
AU724488B2 (en) 2000-09-21
CN1237905A (zh) 1999-12-08
CA2266401C (en) 2007-01-30
US20040077730A1 (en) 2004-04-22
SK31999A3 (en) 1999-12-10
HRP970505A2 (en) 1998-08-31

Similar Documents

Publication Publication Date Title
IL128850A (en) Pharmaceutical composition comprising substituted or unsubstituted n, n-1[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride monohydrate for reducing insulin resistance in humans and its manufacture
HUP0004300A3 (en) Pharmaceutical composition comprising (s)-n-ethyl-3-[1-(dimethylamino)ethyl]-n-methyl-phenyl-carbamate and an antioxidant
HUP0200522A3 (en) Triazole compounds with dopamine-d3-receptor affinity, pharmaceutical compositions containing them and their use
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
HUP0100064A3 (en) Synergetic fungicidal combination comprising amides derivative and chlorothalonil and its use
PL313769A1 (en) Azole derivative and pharmaceutical composition thereof
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
IL123013A (en) Substituted imidazoles having biphenylsulfonyl substitution, and pharmaceutical compositions comprising them
IL111148A0 (en) Imidazol-4- ylpiperidine derivatives, their preparation and their application in therapeutics
AU2015399A (en) Pharmaceutical compositions containing bupropion hydrochloride and an inorganic acid stabilizer
HU9600427D0 (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
AU8278498A (en) Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines
HUP0003063A3 (en) Synergetic fungicidal composition and its use
HUP0002361A3 (en) Synergetic fungicidal composition, based on halogenbenzimidazol derivative, manufacture and use thereof
IL118644A0 (en) N-Ú(1,4-diazabicyclo Ú2.2.2¾ oct-2-yl) methyl¾ benzamide derivatives their preparation and their application in therapeutics
HK1048917A1 (zh) 含有n-丙酮基苯甲酰胺和滅菌丹的殺真菌組合物
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL109438A0 (en) 3-Quinolyl-substituted dihydropyridines, processes for their preparation and their use in pharmaceutical compositions
EP0654479A3 (en) Esculetin derivatives, process for their preparation and their use as pharmaceutical compositions.
HUP0002975A3 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate and pharmaceutical composition containing it
HUP0104623A3 (en) Cyclosporin solution, pharmaceutical composition comprising thereof and its use
IL111707A0 (en) Substituted benzimidazole, processes for its preparation and its pharmaceutical use
HK1041689A1 (en) ((Aminoiminomethyl)amino) alkanecarboxamides and their applications in therapy.
HUP0004838A3 (en) Synergetic fungicidal combination comprising benzyl-ether derivative and n-acetonyl-benzamide derivative and its use
AU1255900A (en) Pharmaceutical composition comprising bupropion hydrochloride

Legal Events

Date Code Title Description
HCA Change of name of proprietor(s) after amalgamation
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees